Orion CEO Magali Haas Featured in Partnering for Cures panel: Unlocking the Mysteries of the Human BrainNovember 25, 2014Read more
What if we started diagnosing brain disorders based on physiological measures as opposed to the behavioral measures that are currently in use now? This is the provocative question that kicked off the five-person panel discussion at the sixth annual Partnering for Cures, moderated by Kafui Dzirasa of Duke University Medical Center.
- November 6, 2014Read more
Nature Neuroscience presents a Focus on Big Data in their November Issue
Orion Alliance Leadership Member Philip De Jager, MD, PhD, Awarded the National MS Society’s 2014 Barancik Prize for Innovation in MS ResearchOctober 23, 2014Read more
Philip L. De Jager, MD, PhD, Neurologist at Brigham and Women’s Hospital and Associate Professor of Neurology at Harvard Medical School, is the 2014 recipient of the Barancik Prize for Innovation in MS Research, an international award established in 2013 to drive progress in multiple sclerosis (MS) research. Dr. De Jager, a clinician and a researcher, was selected for his work in applying powerful analytic approaches to better understand how genes and the environment interact with the goal of developing personalized treatments for MS and, ultimately, disease prevention.
Orion CEO Co-Authors 2014 Report on the Milestones for the US National Plan to Address Alzheimer’s DiseaseOctober 20, 2014Read more
Orion CEO & Founder Magali Haas was a co-author of the Alzheimer’s Association 2014 Report on the Milestones for the US National Plan to Address Alzheimer’s Disease. Read the full report here: http://www.alzheimersanddementia.com/article/S1552-5260(14)02791-5/fulltext
- October 20, 2014Read more
2014 KEY OPINION LEADER PROGRAM Thought leaders from industry, academia, government and medical research foundations share their insights on the opportunities and challenges that impact the discovery and development of new therapies. FRESH PERSPECTIVES AND NEW OPPORTUNITIES IN ALZHEIMER’S DISEASE THERAPEUTIC DEVELOPMENT More than 5 million Americans suffer from Alzheimer’s disease today, and without new drugs to prevent or halt